RIT was founded in 1993 by Daniel M. Ritt and Ellen Miller Ritt. RIT received FDA clearance on RIT113 radiation therapy film dosimetry that year, and sold their first system soon thereafter. RIT113's revolutionary innovations provided clinical and research physicists with the first high precision automated QA tool for advanced radiation therapies. RIT quickly became recognized as the leading innovator in precision automated QA, developing the first automated IMRT analysis, which was used by the first commercial IMRT Treatment Planning System manufacturer to document and verify IMRT Dose delivery for its' FDA application.

RIT's IMRT QA analysis provided clinical physicists with the tool necessary to analyze this new advanced cancer treatment, thereby participating in the rapid availability of this treatment, which significantly improves cancer survival rates, to the community hospital level both in the US and worldwide. RIT is the only radiation therapy QA system available that interfaces with every commercially available TPS system, and was the first manufacturer to offer independent dose QA for direct digital images from CR and EPID. RIT software is used in more than 1500 hospitals, including 19 of the Top 20 US Cancer Treatment Hospitals* and in 36 countries worldwide. RIT continues to lead the dosimetry market in innovation and holds many US and international patents on their QA routines.

*US News and World Report Annual Report On Top Hospitals.

Sales Representatives